Co-occurring Mutations of Tumor Suppressor Genes, <i>LATS2</i> and <i>NF2</i>, in Malignant Pleural Mesothelioma.
Tranchant, Robin; Quetel, Lisa; Tallet, Anne; Meiller, Clement; Renier, Annie; de Koning, Leanne; de Reynies, Aurelien; Le Pimpec-Barthes, Francoise; Zucman-Rossi, Jessica; Jaurand, Marie-Claude; Jean, Didier.
Clin Cancer Res
; 23(12): 3191-3202, 2017 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-28003305
Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
[Systemic Treatment of Malignant Pleural Mesothelioma].
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.
Advances in the systemic therapy of malignant pleural mesothelioma.
Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy.
A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.